aTyr Pharma Announces Publication Of Results From Phase 3 EFZO-FIT Study Of Lead Therapeutic Candidate, Efzofitimod, In Patients With Pulmonary Sarcoidosis, In The Lancet Respiratory Medicine

Loading news article.

aTyr Pharma Announces Publication Of Results From Phase 3 EFZO-FIT Study Of Lead Therapeutic Candidate, Efzofitimod, In Patients With Pulmonary Sarcoidosis, In The Lancet Respiratory Medicine | WAPE

aTyr Pharma Announces Publication Of Results From Phase 3 EFZO-FIT Study Of Lead Therapeutic Candidate, Efzofitimod, In Patients With Pulmonary Sarcoidosis, In The Lancet Respiratory Medicine

Article summary

Related companies

Analyzed by WAPE AI.

Comments —